Natera Inc (NTRA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Natera Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 10 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 267.80 $ — 89% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Analysts & Price Target
The price target sits 5.6% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 21
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -1.71 | -2.34 – -1.24 | 2,797 | -12.4% | 14 |
| 12/31/2027 | -0.20 | -2.37 – 1.32 | 3,328 | 88.0% | 14 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.47 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.43 | – | 476 | 53.00 | -11.30 | 53 | 35 |
| 2025: Q1 | -0.50 | – | 502 | 36.50 | -13.30 | 45 | 23 |
| 2025: Q2 | -0.74 | – | 547 | 32.20 | -18.50 | 38 | 12 |
| 2025: Q3 | -0.64 | – | 592 | 34.70 | -14.80 | 59 | 25 |
| 2025: Q4 | 0.35 | – | 666 | 39.80 | 7.10 | 74 | 38 |
| 2026: Q1 | -0.60 | – | 697 | 38.80 | -12.20 | 40 | 18 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 217 | -96 | -96 | -1.86 | -74 | 106 | 211 |
| 2017 | 211 | -134 | -136 | -2.54 | -98 | 25 | 215 |
| 2018 | 258 | -115 | -128 | -2.22 | -71 | 32 | 268 |
| 2019 | 302 | -116 | -125 | -1.79 | -63 | 279 | 583 |
| 2020 | 391 | -216 | -230 | -2.84 | -183 | 486 | 932 |
| 2021 | 625 | -468 | -472 | -5.21 | -335 | 653 | 1,236 |
| 2022 | 820 | -541 | -548 | -5.57 | -432 | 706 | 1,394 |
| 2023 | 1,083 | -446 | -435 | -3.78 | -247 | 765 | 1,442 |
| 2024 | 1,697 | -222 | -190 | -1.53 | 136 | 1,195 | 1,661 |
| 2025 | 2,306 | -310 | -208 | -1.52 | 215 | 1,712 | 2,508 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Natera, Inc. ist ein Diagnostikunternehmen, das weltweit molekulare Testdienste entwickelt und kommerzialisiert.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 6,135 |
| Headquarters | Austin, TX |
| Address | 13011 McCallen Pass, 78753 Austin, United States |
| Phone | 650 980 9190 |
| Website | natera.com |
| IPO Date | 2. Jul 2015 |
| ISIN | US6323071042 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Matthew Rabinowitz Ph.D. | Co-Founder & Executive Chairman | 1973 |
| Steven Leonard Chapman | CEO & Director | 1979 |
| John Fesko | President & Chief Business Officer | 1979 |
| Michael B. Brophy M.B.A. | Chief Financial Officer | 1980 |
| Solomon Moshkevich M.B.A. | President of Clinical Diagnostics | 1982 |
| Jonathan Sheena M.Eng. | Co-Founder & Director | 1973 |
| Olesya A. Anisimova CPA | Chief Accounting Officer | – |
| Rishi Kacker | Chief Technology Officer | – |
| Eric A. Evans Ph.D. | Chief Scientific Officer | – |
| Daniel Rabinowitz L.L.M. | Secretary & Chief Legal Officer | 1969 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 29. Jul 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,863 | 249.38 | 464,595 |
| 28. Jul 2026 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell | 931 | 254.07 | 236,540 |
| 28. Jul 2026 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | Sell | 1,204 | 254.07 | 305,901 |
| 28. Jul 2026 | Rabinowitz Daniel | SEC. AND CHIEF LEGAL OFFICER | Sell | 1,003 | 254.07 | 254,833 |
| 28. Jul 2026 | Chapman Steven Leonard | CEO AND PRESIDENT | Sell | 3,580 | 254.07 | 909,572 |
| 28. Jul 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 170 | 254.33 | 43,237 |
| 28. Jul 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,008 | 253.77 | 255,797 |
| 28. Jul 2026 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | Sell | 1,241 | 254.07 | 315,301 |
| 28. Jul 2026 | Sheena Jonathan | Director | Sell | 191 | 254.07 | 48,527 |
| 27. Jul 2026 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | Sell | 782 | 260.49 | 203,704 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.